IL296038A - Humanized antibody against human pd-1 - Google Patents

Humanized antibody against human pd-1

Info

Publication number
IL296038A
IL296038A IL296038A IL29603822A IL296038A IL 296038 A IL296038 A IL 296038A IL 296038 A IL296038 A IL 296038A IL 29603822 A IL29603822 A IL 29603822A IL 296038 A IL296038 A IL 296038A
Authority
IL
Israel
Prior art keywords
antibody
inhibitors
human
antigen
nucleic acid
Prior art date
Application number
IL296038A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of IL296038A publication Critical patent/IL296038A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL296038A 2018-12-21 2019-12-17 Humanized antibody against human pd-1 IL296038A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306801 2018-12-21
PCT/EP2019/085776 WO2020127366A1 (fr) 2018-12-21 2019-12-17 Anticorps anti-pd-1 anti-humain humanisé

Publications (1)

Publication Number Publication Date
IL296038A true IL296038A (en) 2022-10-01

Family

ID=65628503

Family Applications (2)

Application Number Title Priority Date Filing Date
IL296038A IL296038A (en) 2018-12-21 2019-12-17 Humanized antibody against human pd-1
IL283812A IL283812B2 (en) 2018-12-21 2021-06-08 Humanized antibody against human pd–1

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL283812A IL283812B2 (en) 2018-12-21 2021-06-08 Humanized antibody against human pd–1

Country Status (19)

Country Link
US (2) US11352430B2 (fr)
EP (2) EP4257199A3 (fr)
JP (2) JP7043685B2 (fr)
KR (2) KR102371173B1 (fr)
CN (2) CN116063513A (fr)
AR (1) AR117465A1 (fr)
AU (1) AU2019406452B2 (fr)
BR (1) BR112021011982A2 (fr)
CA (1) CA3122526C (fr)
CL (1) CL2021001628A1 (fr)
CO (1) CO2021007956A2 (fr)
DK (1) DK3883966T3 (fr)
EA (1) EA202191751A1 (fr)
ES (1) ES2963700T3 (fr)
IL (2) IL296038A (fr)
MX (1) MX2021007290A (fr)
SG (1) SG11202106347PA (fr)
TW (1) TW202037608A (fr)
WO (2) WO2020127366A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11325959B2 (en) 2017-01-25 2022-05-10 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
US20230071889A1 (en) * 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
JP2023554097A (ja) 2020-12-17 2023-12-26 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ１／ｉｌ－７分子
CN114763384B (zh) * 2021-01-14 2023-03-17 立凌生物制药(苏州)有限公司 靶向pd-1的单域抗体及其衍生物和用途
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
EP4320156A1 (fr) 2021-04-09 2024-02-14 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
TWI833242B (zh) * 2021-06-11 2024-02-21 大陸商廣東菲鵬製藥股份有限公司 抗pd-1人源化抗體或其抗原結合片段、編碼其的核酸、包含其的載體、細胞和藥物組合物及其用途
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
WO2024077069A1 (fr) * 2022-10-05 2024-04-11 Chulalongkorn University Anticorps monoclonaux dirigés contre la protéine 1 de mort cellulaire programmée humaine (pd-1)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5275285A (en) 1992-12-30 1994-01-04 Clegg Industries Business card holder with sound generating microchip
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
DK2992017T3 (da) * 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
AU2015247358B2 (en) 2014-04-18 2020-02-27 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
CN105330740B (zh) * 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
TWI751981B (zh) 2015-10-02 2022-01-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
BR112018014615A2 (pt) 2016-01-20 2018-12-11 The Scripps Research Institute composições de anticorpo para ror1 e métodos relacionados
IL306104A (en) 2016-09-14 2023-11-01 Abbvie Biotherapeutics Inc Antibodies against (CD27) PD-1
CA3049449A1 (fr) 2017-01-18 2018-07-26 Visterra, Inc. Conjugues molecule d'anticorps-medicament et leurs utilisations
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
US11555072B2 (en) 2017-09-23 2023-01-17 Memorial Sloan Kettering Cancer Center A33 antibody compositions and methods of using the same in radioimmunotherapy
US20210024632A1 (en) 2018-03-05 2021-01-28 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
BR112021012027A2 (pt) 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula bifuncional direcionada contra pd-1 humano
AU2019409805A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule

Also Published As

Publication number Publication date
ES2963700T3 (es) 2024-04-01
KR102371173B1 (ko) 2022-03-04
IL283812B (en) 2022-10-01
CN113557245B (zh) 2022-10-25
IL283812B2 (en) 2023-02-01
CN113557245A (zh) 2021-10-26
WO2020127366A1 (fr) 2020-06-25
JP2022075824A (ja) 2022-05-18
EP3883966A1 (fr) 2021-09-29
TW202037608A (zh) 2020-10-16
JP7404423B2 (ja) 2023-12-25
JP2022513528A (ja) 2022-02-08
EP4257199A2 (fr) 2023-10-11
IL283812A (en) 2021-07-29
US11352430B2 (en) 2022-06-07
EP3883966B1 (fr) 2023-07-12
AU2019406452A1 (en) 2021-07-08
CA3122526A1 (fr) 2020-06-25
US20220332826A1 (en) 2022-10-20
AU2019406452B2 (en) 2021-09-16
AR117465A1 (es) 2021-08-11
JP7043685B2 (ja) 2022-03-29
DK3883966T3 (da) 2023-10-16
SG11202106347PA (en) 2021-07-29
EA202191751A1 (ru) 2021-10-12
MX2021007290A (es) 2022-03-17
US20210355225A1 (en) 2021-11-18
CN116063513A (zh) 2023-05-05
CO2021007956A2 (es) 2021-10-29
WO2020127367A1 (fr) 2020-06-25
EP4257199A3 (fr) 2024-01-10
KR20220032646A (ko) 2022-03-15
BR112021011982A2 (pt) 2021-09-14
CL2021001628A1 (es) 2022-01-07
CA3122526C (fr) 2023-01-03
KR20210097197A (ko) 2021-08-06

Similar Documents

Publication Publication Date Title
AU2019406452B2 (en) Humanized anti-human-PD-1 antibody
US20200268901A1 (en) Antibodies comprising modified heavy constant regions
EP3897845A1 (fr) Molécule bifonctionnelle dirigée contre le pd-1 humain
US20220056135A1 (en) Bifunctional anti-pd-1/sirpa molecule
US20230071889A1 (en) Bifunctional anti-pd-1/il-7 molecule
WO2018218056A1 (fr) Anticorps comprenant des régions constantes de chaîne lourde modifiées
WO2020165374A1 (fr) Molécule bifonctionnelle comprenant il-15ra
US20240182572A1 (en) Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains